Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following ...

Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics with the potential to restore synapses that could improve the lives of patients worldwide, today ...

ADS051 is the first and only MRP2 / FPR1 inhibitor to demonstrate favorable safety and tolerability with signals of clinical efficacy with relief from disruptive symptoms of inflammatory bowel disease ...

Schematic diagram (a) and photo (b) of the fabricated gas-filled hollow-core fiber phase modulator. (c) Measured loss spectrum and (d) transient response of the phase modulator. Credit: ...

WATERTOWN, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease ...

This study demonstrates a compact optical modulation platform that enables real-time, high-resolution spectroscopy using sub-MHz interleaved combs generated via chip-scale acousto-optic phase ...

SOUTH SAN FRANCISCO, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug ...

Neuphoria’s social anxiety disorder program will be discontinued based on the results from the AFFIRM-1 trial. Topline results were announced from a phase 3 trial evaluating BNC210 in patients with ...